publicli
fund
repositori
covid
databas
right
unrestrict
research
reus
analys
form
mean
acknowledg
origin
sourc
permiss
grant
free
elsevi
long
resourc
centr
remain
activ
arch
bronconeumol
w
w
w
r
c
h
b
r
n
c
n
e
u
l
r
g
accord
estim
around
million
case
pneumonia
occur
worldwid
everi
year
caus
million
death
account
overal
mortal
worldwid
fourth
caus
death
worldwid
particularli
seriou
threat
children
elderli
bacteri
infect
common
extens
studi
contrast
research
viral
communityacquir
pneumonia
cap
despit
grow
epidemiolog
signific
develop
countri
pediatr
popul
limit
assum
rate
diagnosi
still
lower
real
incid
around
million
case
viral
pneumonia
occur
annual
throughout
world
half
children
viral
pneumonia
great
interest
due
impact
infant
mortal
role
facilit
bacteri
infect
coinfect
eas
transmiss
factor
transform
worldwid
threat
review
focu
cap
caus
respiratori
virus
immunocompet
patient
import
distinguish
cap
viral
bacteri
origin
clinic
radiolog
laboratori
variabl
commonli
use
distinguish
entiti
list
tabl
epidemiolog
studi
publish
mani
author
et
al
includ
patient
viral
intracellular
bacteri
pneumonia
group
conclud
pneumonia
caus
intracellular
pathogen
affect
older
patient
insidi
diseas
cours
often
produc
leukocytosi
johnston
et
al
found
patient
viral
pneumonia
cardiac
comorbid
older
et
al
found
institution
led
greater
risk
viral
cap
liu
et
al
report
viral
pneumonia
caus
cough
less
pleurit
pain
jen
et
al
found
myalgia
symptom
commonli
associ
viral
diseas
despit
mani
public
predict
viral
etiolog
clinic
paramet
difficult
often
inaccur
affirm
recent
viasu
et
al
regard
radiolog
chang
focal
alveolar
infiltr
tradit
associ
bacteri
entiti
bilater
interstiti
infiltr
viral
form
howev
recent
studi
use
chest
comput
tomographi
ct
shown
viral
etiolog
rule
appear
local
alveolar
infiltr
may
even
signal
onset
mani
viral
pneumonia
viral
infect
usual
affect
number
leukocyt
use
acut
phase
reactant
procalcitonin
biomark
may
great
help
reach
diagnosi
procalcitonin
product
depend
presenc
circul
tumor
necrosi
factor
viral
infect
macrophag
produc
inhibit
suppress
elev
procalcitonin
thu
suggest
viral
origin
despit
assert
gold
standard
differenti
etiolog
pneumonia
moreov
must
forget
cap
whether
viral
bacteri
dynam
entiti
differ
biomark
valu
appear
infiltr
radiolog
snapshot
activ
process
vari
wide
day
day
list
virus
caus
respiratori
infect
long
tabl
review
focu
particularli
season
respiratori
virus
virus
recent
receiv
consider
media
attent
influenza
viru
coronavirus
respons
sever
acut
respiratori
syndrom
middl
east
respiratori
syndrom
merscov
examin
less
depth
rel
incid
clinic
epidemiolog
characterist
differ
respiratori
virus
list
tabl
overal
syncyti
respiratori
viru
srv
remain
primari
caus
agent
cap
children
main
caus
sever
pneumonia
popul
sinc
widespread
introduct
pcr
techniqu
rhinovirus
often
detect
caus
agent
viral
pneumonia
children
howev
frequent
detect
asymptomat
individu
etiolog
role
rhinoviru
continu
question
although
could
indic
real
subclin
infect
recent
identifi
pathogen
metapneumoviru
human
bocaviru
less
commonli
encount
although
preval
viral
pneumonia
caus
adenoviru
low
must
identifi
lead
necrot
pneumonia
case
pcr
techniqu
much
sensit
antigen
detect
techniqu
case
adult
commonli
detect
virus
influenza
viru
iv
srv
parainfluenza
although
incid
vari
depend
diagnost
techniqu
use
virus
also
import
spain
pneumonia
caus
virus
rare
report
includ
outbreak
rhinoviru
adenoviru
particularli
serotyp
militari
institut
coronaviru
metapneumoviru
even
bocaviru
immunocompromis
patient
infect
involv
respiratori
bacteria
virus
differ
virus
common
wide
accept
hypothesi
viral
infect
occur
first
follow
bacteri
form
viralmedi
activ
proinflammatori
molecul
thought
attract
larg
number
neutrophil
macrophag
lung
arriv
cytokin
amplifi
immun
respons
caus
inflammatori
damag
prevent
proper
clearanc
bacteria
bacteri
superinfect
worsen
prognosi
origin
viral
infect
inde
research
influenza
pandem
show
death
caus
secondari
bacteri
infect
pandem
case
present
secondari
bacteri
infect
infect
caus
virus
howev
especi
avian
influenza
associ
pneumonia
appear
caus
frequent
direct
viral
action
clinic
practic
type
coinfect
particularli
common
children
case
cap
mainli
involv
pneumococcu
thu
increas
clinic
sever
mycoplasma
pneumonia
sever
speci
chlamydophila
also
common
simultan
coinfect
virus
unusu
cap
mix
etiolog
character
less
adult
children
preval
estim
less
common
combin
report
rhinoviruspneumococcu
influenza
viruspneumococcu
seriou
infect
identifi
combin
virus
legionella
pneumophila
data
morbid
mortal
bacterialvir
coinfect
contradictori
hong
et
al
consid
coinfect
sever
pure
bacteri
infect
affect
older
patient
chronic
lung
diseas
contrast
johansson
et
al
seki
et
al
found
mix
etiolog
pneumonia
associ
higher
sever
scale
score
poorer
progress
wellknown
famili
respiratori
virus
produc
new
speci
virul
serotyp
recent
year
caus
epidem
signific
associ
morbid
mortal
great
iva
epidem
unusu
transmiss
enhanc
lack
prior
immun
caus
seriou
medic
situat
worldwid
studi
perform
subsequ
show
younger
popul
certain
risk
group
affect
result
loss
mani
lifeyear
howev
intergener
perspect
burden
death
major
complic
higher
caus
normal
season
influenza
outbreak
coronaviru
far
east
caus
sever
acut
respiratori
syndrom
middl
east
anoth
outbreak
new
coronaviru
occur
call
middl
east
respiratori
syndrom
coronaviru
merscov
epidem
incid
reduc
hundr
case
partli
due
protect
measur
implement
mortal
high
due
high
virul
clinic
symptom
limit
rapidli
develop
bilater
pneumonia
also
includ
acut
renal
failur
sever
hematolog
disturb
recombin
anim
differ
iv
subtyp
global
concern
potenti
capabl
pass
speci
barrier
occasion
propag
among
human
seriou
case
avian
influenza
record
southeast
asia
recent
variant
unit
state
avian
influenc
china
exampl
new
threat
fortun
surveil
system
monitor
anim
reserv
activ
rapid
medic
respons
improv
detect
viru
viral
antigen
upper
nasopharyng
aspir
lower
bronchoalveolar
lavag
induc
sputum
respiratori
tract
sampl
usual
base
cultur
immunofluoresc
microscopi
detect
antibodi
gener
process
viral
infect
also
use
year
seroconvers
sampl
obtain
period
time
suggest
new
exposur
pathogen
introduct
polymeras
chain
reaction
pcr
techniqu
improv
detect
respiratori
virus
particularli
use
realtim
techniqu
prefer
specimen
upper
respiratori
sampl
particularli
children
nasopharyng
aspir
combin
mixtur
nasal
retropharyng
secret
use
steril
cotton
wool
swab
yield
similar
sensit
virus
except
srv
devic
combin
nylon
fiber
swab
contain
univers
transport
medium
provid
high
diagnost
yield
age
compar
nasopharyng
lavag
sampl
lower
respiratori
tract
obtain
site
infect
obviou
advantag
determin
caus
pneumonia
howev
contamin
may
occur
sampl
specimen
pass
upper
airway
induc
sputum
often
obtain
children
bronchoalveolar
lavag
prefer
adult
contrast
invas
charact
form
diagnosi
transthorac
punctur
led
disus
sampl
process
pcrbase
system
time
sensit
convent
method
detect
respiratori
virus
techniqu
particularli
use
elderli
often
lower
nasopharyng
viral
burden
children
moreov
virus
bocaviru
hard
cultur
antigen
test
may
equivoc
eg
parainfluenza
adenoviru
satisfactorili
identifi
use
pcr
standard
identif
test
develop
use
pcr
platform
combin
microarray
simultan
determin
differ
respiratori
virus
platform
techniqu
commonli
use
hospit
moment
sinc
end
last
centuri
empir
antibiot
treatment
cap
initi
soon
possibl
shown
reduc
morbid
mortal
howev
prospect
studi
examin
benefit
antibiot
pneumonia
high
suspicion
viral
origin
possibl
bacteri
superinfect
mix
viralbacteri
etiolog
progress
improv
antibiot
toler
medicalleg
requir
use
avail
measur
mean
physician
unlik
resist
prescrib
antibiot
patient
present
pneumonia
dilemma
prospect
studi
children
context
srv
bronchiol
epidem
result
definit
support
gener
administr
antibiot
experi
use
antivir
drug
respiratori
virus
divid
area
treatment
influenza
viru
rel
effect
well
document
thank
mainli
studi
perform
pandem
b
treatment
srv
mostli
explor
children
immunosuppress
popul
although
result
remain
unclear
c
treatment
respiratori
virus
studi
depth
remain
larg
unevalu
neuraminidas
enzym
iv
capsid
essenti
intercellular
viral
propag
select
inhibitor
enzym
oseltamivir
zanamivir
peramivir
seen
contain
infect
peak
viral
replic
first
hour
improv
clinic
symptom
reduc
morbid
mortal
retrospect
studi
patient
diagnosi
influenza
shown
reduct
incid
pneumonia
patient
receiv
earli
treatment
although
drug
activ
subtyp
season
epidem
oseltamivirresist
iva
describ
guidelin
recommend
zanamivir
firstlin
approach
pandem
strain
gener
show
resist
profil
wide
treat
oseltamivir
detriment
outcom
children
clinic
effect
less
clear
administr
appear
safe
laninamivir
octano
new
neuraminidas
inhibitor
inhal
administr
seen
effect
treatment
iv
infect
includ
oseltamivirresist
strain
adamantan
amantadin
rimantadin
drug
convent
use
iv
infect
exclus
specif
influenza
viru
type
along
potenti
side
effect
rapid
develop
resist
meant
fallen
disus
clinic
practic
drug
block
rna
product
other
limit
viral
integr
investig
clinic
trial
start
studi
also
conduct
immunomodul
aim
reduc
viralmedi
inflamm
allevi
effect
host
none
treatment
test
significantli
use
manag
acut
episod
pneumonia
improv
respiratori
paramet
followup
accord
largest
metaanalysi
perform
children
date
inhal
ribavirin
pneumonia
reduc
hospit
stay
time
mechan
ventil
significantli
improv
overal
mortal
intraven
oral
administr
ribavirin
use
almost
exclus
sever
immunocompromis
patient
bone
marrow
lung
transplant
recipi
outcom
posit
result
applic
patient
use
immunoglobulin
children
shown
benefit
support
treatment
alon
gener
use
bronchodil
corticosteroid
antibiot
recommend
american
pediatr
guidelin
srv
bronchiol
trial
current
underway
new
product
catelicidin
vitamin
deriv
dingchuan
decoct
chines
medicin
product
result
promis
recent
support
treatment
avail
howev
antivir
medic
current
investig
cytidin
analog
cidofovir
origin
develop
treatment
cmv
shown
success
vitro
adenovirus
although
respons
immunocompromis
patient
sever
form
sever
pneumonia
poor
intraven
ribavirin
use
success
lung
transplant
recipi
respiratori
infect
caus
metapneumoviru
pleconaril
incorpor
capsid
rhinoviru
enteroviru
success
use
limit
case
seri
yet
market
limit
compassion
use
littl
doubt
intraven
acyclovir
benefici
rare
case
varicella
zoster
pneumonia
immunocompromis
patient
lastli
treatment
highdos
corticosteroid
improv
clinic
cours
viral
cap
although
applic
still
controversi
infecti
contagi
diseas
particularli
respiratori
tract
barrier
method
essenti
prevent
infect
use
mask
glove
handwash
shown
effect
reduc
transmiss
rate
healthcar
set
social
isol
patient
clinic
phase
diseas
also
strongli
recommend
reduc
overal
incid
howev
difficult
implement
measur
properli
immun
play
import
role
prevent
avail
virus
antiinfluenza
b
vaccin
shown
reduc
transmiss
season
influenza
epidem
gener
popul
effect
cours
pneumonia
mortal
clear
effici
children
younger
year
although
continu
administ
mani
countri
contrast
appear
effect
elderli
institution
subject
current
recommend
spain
patient
respiratori
comorbid
immunosuppress
individu
year
age
healthcar
worker
addit
vaccin
chemoprophylaxi
neuroaminidas
inhibitor
success
test
season
influenza
epidem
yet
effect
vaccin
avail
srv
palivizumab
use
chemoprophylaxi
human
monoclon
antibodi
shown
reduct
incid
pneumonia
associ
hospit
admiss
neonat
high
risk
infect
